Brief: Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing
26/03/2025 21:05
March 26 (Reuters) - Relmada Therapeutics Inc RLMD.O: RELMADA THERAPEUTICS INC -ON MARCH 24, ENTERS EXCLUSIVE LICENSE AGREEMENT WITH TRIGONE PHARMA - SEC FILING RELMADA THERAPEUTICS INC - TO PAY $3.5 MILLION INITIAL LICENSE FEE TO TRIGONE - SEC FILING Source text: [ID:n0001013762-25-002786] Further company coverage: RLMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million